Memory T Lymphocytes in Cancer Immunology (R21)
The summary for the Memory T Lymphocytes in Cancer Immunology (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Memory T Lymphocytes in Cancer Immunology (R21): - This funding opportunity announcement (FOA) solicits Exploratory/Developmental (R21) grant applications from applicant organizations that propose to conduct basic research studies that are relevant to anti-tumor immunity and that are focused on memory T lymphocytes and/or the cells and molecules that interact with memory T lymphocytes. Such research may include investigations of T memory cell differentiation, maintenance, and re-activation. Investigations may entail both human and animal studies, and both in vitro and in vivo analyses. Innovative uses of existing technologies and reagents, as well as the development of new technologies and reagents, are encouraged. We anticipate that the results of such research will ultimately improve the prospects for successful cancer immunotherapies and cancer vaccine development.-This FOA will utilize the Exploratory/Developmental (R21) grant mechanisms and runs in parallel with a FOA of identical scientific scope, PA-06-350, that solicits applications under the R01 mechanism.-Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received.-The total project period for an application submitted in response to this funding opportunity may not exceed two years. Direct costs are limited to $275,000 over an R21 2-year period, with no more than $200,000 in direct costs allowed in any single year.-Eligible organizations include: for profit organizations; non-profit organizations; public or private institutions, such as universities, colleges, hospitals and laboratories; units of State governments; units of local governments; eligible institutions of the Federal government; domestic institutions; and foreign institutions. -Eligible Project Directors/Principal Investigators (PD/PIs): Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.-Applicants may submit more than one application, provided each application is scientifically distinct
|Federal Grant Title:||Memory T Lymphocytes in Cancer Immunology (R21)|
|Federal Agency Name:||National Institutes of Health|
|Grant Categories:||Education Health|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||PA-06-349|
|Type of Funding:||Grant|
|CFDA Descriptions:||Cancer Biology Research|
|Current Application Deadline:||No deadline provided|
|Original Application Deadline:||Multiple Receipt Dates - See Link to Full Announce|
|Posted Date:||Apr 13, 2006|
|Creation Date:||Apr 13, 2006|
|Archive Date:||Dec 05, 2008|
|Total Program Funding:|
|Maximum Federal Grant Award:||$200,000|
|Minimum Federal Grant Award:|
|Expected Number of Awards:|
|Cost Sharing or Matching:||No|
- Applicants Eligible for this Grant
- Others (see text field entitled "Additional Information on Eligibility" for clarification) Special district governments For profit organizations other than small businesses Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education State governments Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts Public housing authorities/Indian housing authorities County governments City or township governments
- Additional Information on Eligibility
- Foreign institutions are eligible to apply. Eligible agencies of the Federal Government are eligible to apply. Domestic Institutions
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
- Similar Government Grants
- • Administrative Supplements to Promote Research Collaborations on Fusion Oncoproteins as Dr...
- • The Role of Mobile Genetic Elements in Cancer (R21)
- • Development of Innovative Informatics Methods and Algorithms for Cancer Research and Manag...
- • Sustained Support for Informatics Resources for Cancer Research and Management (U24)
- • Advanced Development of Informatics Technologies for Cancer Research and Management (U24)
- • Mouse Models of Human Cancers Consortium
- • Integrative Cancer Biology Programs
- • Memory T Lymphocytes in Cancer Immunology (R01)
- More Grants from the National Institutes of Health
- • Limited Competition for NIH-Industry Program: Discovering Pediatric New Therapeutic Uses f...
- • Environmental influences on Placental Origins of Development (ePOD) (R01)
- • Limited Competition for NIH-Industry Program: Discovering New Therapeutic Uses for Existin...
- • Pre-application for the NIH-Industry Program: Discovering New Therapeutic Uses for Existin...
- • Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01)